(Q37090735)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

0 references

Javier Martinez-Picado

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Miguel A Martinez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Javier Martinez-Picado

1

1 reference

18 August 2017

Miguel Angel Martínez

2

1 reference

18 August 2017

language of work or name

1 reference

4 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

134

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

104-123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

A novel small reporter gene and HIV-1 fitness assay

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

The role of viral fitness in HIV pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Persistence of primary drug resistance among recently HIV-1 infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Procedures for reliable estimation of viral fitness from time-series data.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Can a K103N HIV strain stably overcome the wild type in the absence of non-nucleoside reverse transcriptase inhibitor selective pressure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Pressure of zidovudine accelerates the reversion of lamivudine resistance-conferring M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

RNA virus mutations and fitness for survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Viruses as quasispecies: biological implications

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Selforganization of matter and the evolution of biological macromolecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A whole-genome association study of major determinants for host control of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Fitness landscape of human immunodeficiency virus type 1 protease quasispecies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A fossil record of zidovudine resistance in transmitted isolates of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Protease inhibitor-resistant HIV-1 from patients with preserved CD4 cell counts is cytopathic in activated CD4 T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Antiretroviral-drug resistance among patients recently infected with HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Estimating relative fitness in viral competition experiments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Risk of selecting resistance mutations during treatment interruption.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Targeting HIV: antiretroviral therapy and development of drug resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Insertions and deletions in HIV-1 reverse transcriptase: consequences for drug resistance and viral fitness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral Treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Tryptophan scanning mutagenesis of aromatic residues within the polymerase domain of HIV-1 reverse transcriptase: critical role of Phe-130 for p51 function and second-site revertant restoring viral replication capacity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Primary and recombinant HIV type 1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Fitness of drug resistant HIV-1: methodology and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Retroviral mutation rates and reverse transcriptase fidelity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Persistence of earlier HIV-1 drug resistance mutations at new treatment failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in rep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

(Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants [...]

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2007.12.021

7 January 2021

10.1016/J.VIRUSRES.2007.12.021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18289713%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference